HMS-CSSA Career Development Panel: Careers Beyond Academia

Oct - 04
2019

HMS-CSSA Career Development Panel: Careers Beyond Academia

An Xiao

HMS-CSSA Career Development Panel
Careers Beyond Academia

你是否放弃了寻找教职岗位，想进入工业界工作，但却不知如何着手准备？

你是否厌倦了没日没夜做实验的“生活”，对科研失去了兴趣，想寻求其它的职业发展方向？

亦或是你只想探索更多的职业选择？

如果是，请一定要加入HMS-CSSA举办的专题讨论会：CAREERS BEYOND ACADEMIA.

向成功进入工业界和投资界的师兄师姐们取经学习，复制他们的成功之路!

这一次，我们邀请的分享嘉宾阵容堪称豪华，他们分别是: 来自BeiGene的 Head of Corporate Strategy, Dr. Lucy Li; 5AM Ventures 的分析师Dr. Pengpeng Li; GSK 的Director of Translational Oncology, Dr. Ming Shan; Moderna, Inc. 的Senior Scientist Dr. Zhen Zhang 以及 Bluebird Bio 的Scientist Dr. Jingyu Amy Peng.

时间：2019年10月12日下午14:00-16:00

地点: Smith 308, Dana-Farber Cancer Institute. 1 Jimmy Fund Way, Boston, MA 02115.

期待你的加入！

活动注册：https://www.eventbrite.com/o/hms-cssa-14761532440

嘉宾信息如下：

01 Lucy Li, Ph.D.

Lucy Li is Head of Corporate Strategy at BeiGene, a global, commercial-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. Lucy joined BeiGene in 2015, which IPO’d on the NASDAQ in 2016 and listed on the Hong Kong exchange in 2018. Prior to BeiGene, Lucy spent several years working as a strategy consultant to the life sciences industry. She holds a PhD in Neurology and Neurosciences from Washington University in St. Louis and a BS in Biological Sciences from    Peking University.

02 Zhen Zhang, Ph.D.

Zhen Zhang is a Senior Scientist at Moderna, Inc., a clinical stage biotechnology company pioneered on mRNA based drug discovery. Zhen joined Moderna in 2015. He is a postdoctoral fellow at DFCI and Columbia University before that. He holds a PhD in Biochemistry and structural biology from Baylor College of Medicine and a MS in Chemistry from Peking University.

03 Pengpeng Li, Ph.D.

Pengpeng Li joined 5AM Ventures in 2019 and serves as a 4:59 Analyst. Prior to joining 5AM, she was a HHMI-Helen Hey Whitney Foundation Postdoctoral Fellow at Boston Children’s Hospital and Harvard Medical School, where she studied human brain development using single-cell technologies in Christopher A. Walsh’s laboratory. Dr. Li obtained her Ph.D. in Biology from Stanford University and received HHMI International Predoctoral Fellowship to study neural development where she graduated with the Frances Lou Kallman Award. Her work has been published in Science, Cell, Neuron, among others. She received her B.S. in Biology from Peking University.

04 Ming Shan, Ph.D.

Ming Shan is a Director of Translational Oncology at GSK, a global immuno-oncology and multi-therapeutic area pharma company. Ming spent several years as Principal Scientist at TESARO (later acquired by GSK), and Senior Scientist at Merck, focusing on identifying novel targets for early discovery in both autoimmunity and immuno-oncology, working on end-to-end drug discovery, and leading cell assay development. He holds a PhD in Immunology from Baylor College of Medicine, with Post-doc experiences at Baylor and subsequently at Washington University in St. Louis. Ming got BS in Biological Sciences from Peking University.

05 Jingyu Amy Peng Ph.D.

Jingyu Amy Peng is a Scientist at Bluebird Bio, a pioneering gene therapy biotech company focusing on developing gene therapy and cell therapy for severe genetic diseases and cancer. Amy joined Bluebird Bio early 2019 after her 3-yr postdoc training at DFCI/HMS, during which she was a board member of the HMS-CSSA. She holds a PhD in Molecular Biology and Biochemistry from Peking University and a BS in Biology from East China Normal University.

撰文：王强
校正：陶建立
编辑：李江

参见微信公众号文章